An Unexpected Result of Obesity Treatment: Orlistat-Related Acute Pancreatitis
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Orlistat is a pancreatic lipase inhibitor which is used to treat obesity. Due to the increasing prevalence of obesity, orlistat use is thought to rise progressively. We report an interesting case caused by orlistat use caught in the early stages of acute pancreatitis through imaging; in addition, the case had significantly elevated serum amylase levels. A 54-year-old male who had a history of orlistat treatment started 7 days before was admitted to the emergency department with complaints of abdominal pain, nausea and vomiting lasting for 24 h. Abdominal computed tomography revealed peripancreatic fat tissue edema and a heterogeneous appearance of the pancreas. Based on these findings, it was concluded that edematous pancreatitis was in its initial stage. Orlistat is a drug that is increasingly widespread use due to obesity. More attention must be paid when planning to prescribe orlistat to patients if there are risk factors for acute pancreatitis (alcohol use, height, serum calcium and lipid levels).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Side effects include oily discharge with flatus from the rectum, fecal urgency, and increased defecation and fecal incontinence, especially after fatty food intake.”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [48]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“May promote gallstones and kidney stones.”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [48]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Contraindicated in chronic malabsorption syndrome and cholestasis.”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [48]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“May cause malabsorption of fat-soluble vitamins (A, D, E, K).”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [48]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Approved for patients 12 years or older.”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [48]
Experimental — accuracy not yet measured
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Whitcomb, D. C. (2006) · New England Journal of Medicine · doi:10.1056/nejmcp054958 · Cited by 745
Orlistat-Associated Adverse Effects and Drug Interactions: A Critical Review
Filippatos, T. D., Derdemezis, C. S., Gazi, I. F., Nakou, E. S., Mikhailidis, D. P., & Elisaf, M. S. (2008) · Drug Safety · doi:10.2165/00002018-200831010-00005 · Cited by 434
Guerciolini, R. (1997) · PubMed · Cited by 331
Drug-Induced Pancreatitis: Incidence, Management and Prevention
Balani, A. R., & Grendell, J. H. (2008) · Drug Safety · doi:10.2165/00002018-200831100-00002 · Cited by 285
Drug-induced acute pancreatitis: a review.
Jones, M. R., Hall, O. M., Kaye, A. M., & Kaye, A. D. (2015) · PubMed · Cited by 251
Wilmink, T. B. M., & Frick, T. W. (1996) · Drug Safety · doi:10.2165/00002018-199614060-00006 · Cited by 140
Orlistat (Xenical)-induced subacute liver failure
Thurairajah, P. H., Syn, W., Neil, D., Stell, D. A., & Haydon, G. H. (2005) · European Journal of Gastroenterology & Hepatology · doi:10.1097/01.meg.0000187680.53389.88 · Cited by 54
Orlistat associated subacute hepatic failure
Montero, J. L., Muntané, J., Fraga, E., Delgado, M. B., Costán, G., Serrano, M., Ruiz, F. J. P., de la Mata, M., & Miño, G. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(00)00042-8 · Cited by 37
Acute Pancreatitis Following Orlistat Therapy: Report of Two Cases
Ahmad, F., & Mahmud, S. (2016) · PubMed · doi:10.6092/1590-8577/3874 · Cited by 35
Napier, S., & Thomas, M. G. (2006) · Nutrition Journal · doi:10.1186/1475-2891-5-19 · Cited by 33
Massive Hepatocellular Necrosis: Was it Caused by Orlistat?
Lau, G., & Chan, C. L. (2002) · Medicine Science and the Law · doi:10.1177/002580240204200405 · Cited by 27
Is, S., Yf, L., Cm, C., & Tj, C. (1984) · PubMed · Cited by 26
[A case of acute cholestatic hepatitis associated with Orlistat].
Kim, D. H., Lee, E. H., Hwang, J. C., Jeung, J. H., Kim, D. H., Cheong, J. Y., Cho, S. W., & Kim, Y. B. (2002) · PubMed · Cited by 15
Drug-induced acute pancreatitis
Bellocchi, M. C. C. (2015) · doi:10.3998/panc.2015.32 · Cited by 14
Effects of orlistat and its relationship with nitric oxide in the small intestinal mucosa.
Caner, M., Doğruman, H., Taşkın, E., Kandil, A., & Demirci, C. (2005) · PubMed · Cited by 14
Pancreatitis aguda inducida por orlistat
Aguilera, X. G., Teruel, C., Pérez, L. C., & Vicente, V. M. (2008) · Medicina Clínica · doi:10.1157/13119725 · Cited by 6
Cited by
Khatua, B., El-Kurdi, B., & Singh, V. P. (2017) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000386 · Cited by 206
Mechanisms underlying UCP1 dependent and independent adipocyte thermogenesis
Chang, S., Song, N., Choi, J. H., Yun, U. J., & Park, K. W. (2018) · Obesity Reviews · doi:10.1111/obr.12796 · Cited by 115
Induction of thermogenic adipocytes: molecular targets and thermogenic small molecules
Song, N.-J., Chang, S., Li, D. Y., Villanueva, C. J., & Park, K. W. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.70 · Cited by 84
Bays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
“[18,44,48,60,85] Gastrointestinal events may increase when orlistat is taken with a diet high in fat ( > 30% total daily calories from fat).”
BackgroundDiscovery of Arginine-Containing Tripeptides as a New Class of Pancreatic Lipase Inhibitors
Stefanucci, A., Luisi, G., Zengin, G., Macedonio, G., Dimmito, M. P., Novellino, E., & Mollica, A. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0216 · Cited by 60
Metadata
- Authors
- Kose, M., Emet, S., Akpınar, T. S., Ilhan, M., Gok, A. F. K., Dadashov, M., & Tukek, T.
- Affiliations
- Istanbul University (TR)
- Corresponding author
- Emet, Samim
- Venue
- Case Reports in Gastroenterology
- Publisher
- S. Karger AG
- Published
- 2015-05-08
- Volume
- 9
- Issue
- 2
- Pages
- 152-155
- ISSN
- 1662-0631 (ISSN-L)
- PMC
- PMC4464098
- OpenAlex
- W1602325038
- Cited by
- 36
- References
- 16
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 6 · 2023: 2 · 2022: 4 · 2021: 2 · 2020: 3 · 2019: 1 · 2018: 4 · 2017: 4 · 2016: 1 · 2015: 1
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/3.0/ (vor)
- creativecommons.org/licenses/by-nc/3.0/ (tdm)
- Locations
- Case Reports in Gastroenterology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Gastroenterology › Gallbladder and Bile Duct Disorders
- Keywords
- orlistat, acute pancreatitis, drug-induced pancreatitis, obesity treatment, pancreatic lipase inhibitors, edematous pancreatitis, serum amylase, abdominal CT, adverse drug reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
